Literature DB >> 19139745

Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis.

Arnon Adler1, Arnon Afek, Yair Levy, Gad Keren, Jacob George.   

Abstract

BACKGROUND: A 35-year-old man with primary antiphospholipid syndrome and no risk factors for atherosclerosis presented with postinfarction angina. INVESTIGATIONS: Coronary angiography, intravascular ultrasonography, injection of apolipoprotein-E-knockout mice with patient's IgG. DIAGNOSIS: Myocardial infarction caused by a newly occluded proximal left circumflex artery. The left anterior descending artery exhibited a recanalized thrombus throughout the vessel. MANAGEMENT: The patient was managed by intensive angicoagulation including aspirin, clopidogrel, and enoxaparin for 2 months. After follow-up coronary angiography, he was switched to warfarin with a target International Normalized Ratio of 3.5-4.0.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139745     DOI： 10.1038/ncpcardio1436

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN： 1743-4297


  12 in total

Review 1.  Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome.

Authors:  J George; D Haratz; Y Shoenfeld
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

2.  Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression.

Authors:  J George; D Harats; B Gilburd; A Afek; Y Levy; J Schneiderman; I Barshack; J Kopolovic; Y Shoenfeld
Journal:  Circulation       Date:  1999-05-04       Impact factor: 29.690

Review 3.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

4.  Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I.

Authors:  J George; A Afek; B Gilburd; M Blank; Y Levy; A Aron-Maor; H Levkovitz; A Shaish; I Goldberg; J Kopolovic; D Harats; Y Shoenfeld
Journal:  Circulation       Date:  1998-09-15       Impact factor: 29.690

5.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

6.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

7.  Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice.

Authors:  A Afek; J George; Y Shoenfeld; B Gilburd; Y Levy; A Shaish; P Keren; Z Janackovic; I Goldberg; J Kopolovic; D Harats
Journal:  Pathobiology       Date:  1999       Impact factor: 4.342

8.  Quantitative assessment of atherosclerotic lesions in mice.

Authors:  B Paigen; A Morrow; P A Holmes; D Mitchell; R A Williams
Journal:  Atherosclerosis       Date:  1987-12       Impact factor: 5.162

9.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

10.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.

Authors:  W Palinski; E Miller; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.